170 related articles for article (PubMed ID: 15778396)
1. Activation pathways implicate anti-HLA-DP and anti-LFA-1 antibodies as lead candidates for intervention in chronic berylliosis.
Chou YK; Edwards DM; Weinberg AD; Vandenbark AA; Kotzin BL; Fontenot AP; Burrows GG
J Immunol; 2005 Apr; 174(7):4316-24. PubMed ID: 15778396
[TBL] [Abstract][Full Text] [Related]
2. Beryllium-induced tumor necrosis factor-alpha production by CD4+ T cells is mediated by HLA-DP.
Sawyer RT; Parsons CE; Fontenot AP; Maier LA; Gillespie MM; Gottschall EB; Silveira L; Newman LS
Am J Respir Cell Mol Biol; 2004 Jul; 31(1):122-30. PubMed ID: 14975942
[TBL] [Abstract][Full Text] [Related]
3. HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells.
Amicosante M; Berretta F; Franchi A; Rogliani P; Dotti C; Losi M; Dweik R; Saltini C
Eur Respir J; 2002 Nov; 20(5):1174-8. PubMed ID: 12449171
[TBL] [Abstract][Full Text] [Related]
4. Self-presentation of beryllium by BAL CD4+ T cells: T cell-T cell interactions and their potential role in chronic beryllium disease.
Fontenot AP; Edwards DM; Chou YK; Mack DG; LaTocha D; Vandenbark AA; Burrows GG
Eur J Immunol; 2006 Apr; 36(4):930-9. PubMed ID: 16552706
[TBL] [Abstract][Full Text] [Related]
5. Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells.
Fontenot AP; Keizer TS; McCleskey M; Mack DG; Meza-Romero R; Huan J; Edwards DM; Chou YK; Vandenbark AA; Scott B; Burrows GG
J Immunol; 2006 Sep; 177(6):3874-83. PubMed ID: 16951350
[TBL] [Abstract][Full Text] [Related]
6. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease.
Fontenot AP; Torres M; Marshall WH; Newman LS; Kotzin BL
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12717-22. PubMed ID: 11050177
[TBL] [Abstract][Full Text] [Related]
7. Beryllium presentation to CD4+ T cells is dependent on a single amino acid residue of the MHC class II beta-chain.
Bill JR; Mack DG; Falta MT; Maier LA; Sullivan AK; Joslin FG; Martin AK; Freed BM; Kotzin BL; Fontenot AP
J Immunol; 2005 Nov; 175(10):7029-37. PubMed ID: 16272364
[TBL] [Abstract][Full Text] [Related]
8. Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP.
Fontenot AP; Newman LS; Kotzin BL
Clin Immunol; 2001 Jul; 100(1):4-14. PubMed ID: 11414740
[No Abstract] [Full Text] [Related]
9. Role of high-affinity HLA-DP specific CLIP-derived peptides in beryllium binding to the HLA-DPGlu69 berylliosis-associated molecules and presentation to beryllium-sensitized T cells.
Amicosante M; Berretta F; Dweik R; Saltini C
Immunology; 2009 Sep; 128(1 Suppl):e462-70. PubMed ID: 19191908
[TBL] [Abstract][Full Text] [Related]
10. 4-1BB enhances proliferation of beryllium-specific T cells in the lung of subjects with chronic beryllium disease.
Mack DG; Lanham AK; Palmer BE; Maier LA; Watts TH; Fontenot AP
J Immunol; 2008 Sep; 181(6):4381-8. PubMed ID: 18768897
[TBL] [Abstract][Full Text] [Related]
11. Role of the HLA-DP Glu 69 and the TNF-alpha TNF-alpha 2 gene markers in susceptibility to beryllium hypersensitivity.
Rogliani P; Amicosante M; Berretta F; Dotti C; Bocchino M; O'Donnell KM; Saltini C
Int J Immunopathol Pharmacol; 2004; 17(2 Suppl):3-10. PubMed ID: 15345185
[TBL] [Abstract][Full Text] [Related]
12. HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease.
Lombardi G; Germain C; Uren J; Fiorillo MT; du Bois RM; Jones-Williams W; Saltini C; Sorrentino R; Lechler R
J Immunol; 2001 Mar; 166(5):3549-55. PubMed ID: 11207315
[TBL] [Abstract][Full Text] [Related]
13. CD57 expression correlates with alveolitis severity in subjects with beryllium-induced disease.
Palmer BE; Mack DG; Martin AK; Maier LA; Fontenot AP
J Allergy Clin Immunol; 2007 Jul; 120(1):184-91. PubMed ID: 17416406
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T cells modulate granulomatous inflammation in an HLA-DP2 transgenic murine model of beryllium-induced disease.
Mack DG; Falta MT; McKee AS; Martin AK; Simonian PL; Crawford F; Gordon T; Mercer RR; Hoover MD; Marrack P; Kappler JW; Tuder RM; Fontenot AP
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8553-8. PubMed ID: 24912188
[TBL] [Abstract][Full Text] [Related]
15. Partial IL-10 inhibition of the cell-mediated immune response in chronic beryllium disease.
Tinkle SS; Kittle LA; Newman LS
J Immunol; 1999 Sep; 163(5):2747-53. PubMed ID: 10453017
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of programmed death-1 expression on beryllium-specific CD4+ T cells in chronic beryllium disease.
Palmer BE; Mack DG; Martin AK; Gillespie M; Mroz MM; Maier LA; Fontenot AP
J Immunol; 2008 Feb; 180(4):2704-12. PubMed ID: 18250483
[TBL] [Abstract][Full Text] [Related]
17. Linking genetic susceptibility and T cell activation in beryllium-induced disease.
Falta MT; Bowerman NA; Dai S; Kappler JW; Fontenot AP
Proc Am Thorac Soc; 2010 May; 7(2):126-9. PubMed ID: 20427584
[TBL] [Abstract][Full Text] [Related]
18. Major histocompatibility locus genetic markers of beryllium sensitization and disease.
Saltini C; Richeldi L; Losi M; Amicosante M; Voorter C; van den Berg-Loonen E; Dweik RA; Wiedemann HP; Deubner DC; Tinelli C
Eur Respir J; 2001 Oct; 18(4):677-84. PubMed ID: 11716174
[TBL] [Abstract][Full Text] [Related]
19. Impaired function of CTLA-4 in the lungs of patients with chronic beryllium disease contributes to persistent inflammation.
Chain JL; Martin AK; Mack DG; Maier LA; Palmer BE; Fontenot AP
J Immunol; 2013 Aug; 191(4):1648-56. PubMed ID: 23851684
[TBL] [Abstract][Full Text] [Related]
20. Activation with superantigens induces programmed death in antigen-primed CD4+ class II+ major histocompatibility complex T lymphocytes via a CD11a/CD18-dependent mechanism.
Damle NK; Leytze G; Klussman K; Ledbetter JA
Eur J Immunol; 1993 Jul; 23(7):1513-22. PubMed ID: 8100773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
